Oxcarbazepine NDC 62135-841

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-841Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0841Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-841-24	62135084124	20 CUP, UNIT-DOSE in 1 CARTON (62135-841-24) / 5 mL in 1 CUP, UNIT-DOSE (62135-841-45)Marketed from Mar 27, 2024
62135-841-54	62135084154	250 mL in 1 BOTTLE (62135-841-54)Marketed from Mar 27, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxcarbazepine
Generic name (nonproprietary): oxcarbazepine
Active ingredients: Oxcarbazepine — 300 mg/5mL
Dosage form: Suspension
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212428
Marketing start: Sep 21, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 62135-841_47e4dcae-6305-e681-e063-6294a90a5359SPL ID 47e4dcae-6305-e681-e063-6294a90a5359SPL set ID c2affa00-1d57-4d85-8db3-745191b4714dRxCUI 283536UNII VZI5B1W380UPC 0362135841546
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135084124 followed by a unit qualifier and the quantity

Package 62135-0841-24. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2026.

Indications (excerpt from the label)

Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine oral suspension is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212428

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212428
Product	Strength	Form · route	Labeler	Product NDC
Oxcarbazepine	Oxcarbazepine 300 mg/5mL	SuspensionOral	Chartwell Governmental & Specialty RX, LLC.	68999-841